Xiaoyu Zhu

TL;DR: In women with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines, and/or trastuzumab, pyrotinib plus capecitabine yielded statistically significant better overall response rate and progression-free survival than lapatinibplus cape citabine in this randomized phase II study.

TL;DR: The PHOEBE study as discussed by the authors evaluated the efficacy and safety of pyrotinib plus capecitabine after previous trastuzumab and taxanes for metastatic breast cancer.

TL;DR: In a population largely naïve to HER2-targeted therapy, pyrotinib in combination with capecitabine was well-tolerated and demonstrates promising antitumor activity in patients with Her2-positive metastatic breast cancer.

TL;DR: Pyrotinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor, showed promising anti-tumour activity and acceptable tolerability in patients with HER2+ metastatic breast cancer.

TL;DR: The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China and Fudan University Shanghai Cancer Center, Shanghai, China are cited as sources of inspiration for this work.